• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Anti-Obesity Agents
    5 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    not in the basket chart

    Serotonin 2C Receptor Agonist. Lorcaserin Hydrochloride (hemihydrate) 10.4 mg.
    FILM COAT. TABS.: 60
    The recommended dose 10 mg ×2/d, with / without food. Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, the drug should be discount. See lit.
    Indic. as an adjunct to a reduced-calorie diet and incr.  physic. activity for chron. weight manag. in adult pts. with an initial BMI of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condit. (e.g., hypertens., dyslipidemia, type 2 diabet.).

    partial basket chart

    Uric Acid Production Inhibitor. Febuxostat 80 mg.
    F.C. TABS.:28. 80 mg ×1/d no regard to
    meals. If serum uric acid is > 6 mg/dL
    (357 μmol/L) after 2-4 wks., 120 mg
    ×1/d may be consid. Retest ser. uric
    acid after 2 wks. Gout flare prophylaxis
    of at least 6 mths. is recom.
    Tmt. of chronic hyperuricaemia in cond.
    where urate deposition has already
    occurred (include. a history, presence of,
    tophus and/or gouty arthritis).
    C/I: Hypersens.

    not in the basket chart

    CNS Stimulant. Phentermine (as resinate) 15 mg.
    CAPS (Sustained Action): 30. 1 cap. aft.
    breakf. accord. to instruct.
    Manage. exog. obesity, short term adjust. in
    regimen of wt. reduct. based on calorie

    Novo Nordisk
    not in the basket chart

    Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml.
    PRE-FILL. PENS: 5. Init. 0.6 mg dly. The dose should be incr. to 3.0 mg dly. in increm. of 0.6 mg with at least one week  interv. to improve GI tolerabil. If escal.  to the next dose step is not tolerated for two consec. wks., consider discount. tmt. Dly. doses higher than 3.0 mg are not recomm.
    As an  adjun. a reduced-calorie diet and incr. phys. active. for weight manag. in adult pts. with an init. BMI of  ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid. such as dysglycaemia (pre-diab. or type 2 diab. mell.), hypertens. or dyslipidaemia, and who have failed a prev. weight manag. intervent. Tmt. should be discount. after 12 wks. on the 3.0 mg/day dose if pts. have not lost at least 5% of their init. bdy. wt.

    not in the basket chart

    Lipase Inhibitor. Orlistat 120 mg.
    CAPS: 7, 21, 42, 84 x 120 mg.
    Adults and child over 12 yrs:
    1 cap. 3 x dly.
    In conjunct. with mildly hypocaloric diet
    for obese patients with a BMI greater or
    equal to 30 kg/m2, or overweight patients
    (BMI >28 kg/m2) with assoc. risk factors.
    C/I: Hypersens., chron. malabsorpt.
    syndr., cholestasis, lact.

    Other therapeutic systems under Affecting Nutrition and Metabolism